Royalty Pharma’s first quarter reflected a stable performance, with revenue in line with Wall Street expectations and non-GAAP profitability exceeding consensus. Management highlighted double-digit growth in recurring royalty receipts, driven by the strength of the company’s diversified portfolio and several milestone payments. CEO Pablo Legorreta attributed the results to the company’s efficient business model and active capital deployment, including the initiation of a substantial share buyback program and further investments in new royalty transactions. Notably, management pointed to continued momentum across key assets such as cystic fibrosis therapies and recent additions like Voranigo, as well as an expanded development pipeline.
Is now the time to buy RPRX? Find out in our full research report (it’s free).
Royalty Pharma (RPRX) Q1 CY2025 Highlights:
- Revenue: $568.2 million vs analyst estimates of $570 million (flat year on year, in line)
- Adjusted EPS: $1.06 vs analyst estimates of $0.95 (10.8% beat)
- Adjusted EBITDA: $738 million vs analyst estimates of $703.4 million (130% margin, 4.9% beat)
- Operating Margin: 94%, up from -13% in the same quarter last year
- Market Capitalization: $14.86 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions Royalty Pharma’s Q1 Earnings Call
- Hardik Parikh (JPMorgan) asked about the impact of policy uncertainty on dealmaking and the cystic fibrosis arbitration timeline. CEO Pablo Legorreta noted that policy uncertainty has not reduced deal flow and no updates were available on the Vertex arbitration.
- Mike Nedelcovych (TD Cowen) questioned the effect of tariffs and policy changes on royalty payments and new funding opportunities. CFO Terry Coyne explained tariffs are unlikely to impact royalties, while Legorreta saw potential for Royalty Pharma to fill funding gaps left by NIH cuts.
- Terence Flynn (Morgan Stanley) inquired about the early performance of Alyftrek and the impact of FDA regulatory changes on aficamten. CFO Coyne described Alyftrek’s launch as too early for conclusions, while EVP Marshall Urist said REMS changes were anticipated and the market could support multiple HCM therapies.
- Geoff Meacham (Citi) asked about the decision-making behind share repurchases versus new deals and a possible shift toward first-in-class assets. Coyne reiterated the dynamic allocation approach, and Urist stated the company’s diligence process remains focused on assets with strong patient benefits and scientific merit.
- Jason Gerberry (Bank of America Securities) sought context on ecopipam’s market potential for Tourette’s and parallels to other movement disorders. Urist compared potential market expansion to tardive dyskinesia, citing an unmet need and growing commercial opportunity.
Catalysts in Upcoming Quarters
In future quarters, the StockStory team will be watching (1) clinical and regulatory progress for key development-stage assets like litifilimab and ecopipam, (2) the pace and scale of new royalty acquisitions or capital deployments, and (3) updates on share repurchase activity and changes to capital allocation priorities. We will also look for developments in policy or funding environments that could affect biopharma deal flow and Royalty Pharma’s role as a capital provider.
Royalty Pharma currently trades at $36.08, up from $32.80 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
